AOD-9604 - Composed Monograph

Identity Calibration

Identity warning type: sequence / fragment confusion

“AOD-9604” and “HGH Fragment 176-191” are routinely conflated across vendor catalogues, clinic marketing, and even some peer-reviewed reviews. The two are structurally distinct synthetic peptides:

Molecule	Composition	CAS (canonical)	PubChem CID	MF / MW
AOD-9604 (synthetic)	Tyr-hGH(177-191) - N-terminal tyrosine added to the 15-residue C-terminal hGH sequence; 16 residues total; intramolecular Cys7-Cys14 disulfide bridge	386264-39-7	71300630 (free base); 168310522 (acetate)	C₇₈H₁₂₃N₂₃O₂₃S₂ / ~1815.1 Da
HGH Fragment 176-191	Native hGH residues 176-191; no added Tyr; 16 residues	66004-57-7	172966176 (current PubChem)	C₇₈H₁₂₃N₂₃O₂₂S₂ / ~1799 Da

The two differ by one tyrosine residue and ~16 Da of mass. CAS 221231-10-3 is used interchangeably across Chinese peptide-supplier catalogues for BOTH compounds; the chemically defensible mapping is AOD-9604 → 386264-39-7; HGH Fragment 176-191 → 66004-57-7. [Academic secondary source - PubChem; vendor catalogue cross-check]

Community awareness is partial. r/Peptides thread 1jpjj56 (2025-04-02) is a low-engagement trace example of a community member encountering two vendors with different stated formulas and CAS numbers for what was sold as the same product. An Eroids 2022 AOD-vs-HGH-Frag identity thread makes the same point from the user side: vendor pages can present the compounds as separate products while community reports contest whether the distinction is understood or meaningful in practice. Treating safety, PK or mechanism data from one as transferable to the other is not scientifically defensible.

---

1. Identity

Field	Value	Source
Common name	AOD9604 / AOD-9604	[Regulatory document - FDA PCAC briefing materials, 2024-12-04]
Long name	Anti-Obesity Drug 9604	[Public docket - Edwin Lee MD PCAC slides; flagged not peer-reviewed]
INN	None assigned (no entry in WHO Drug Information lists)	[Regulatory document - WHO]
Chemical description	Synthetic 16-amino-acid peptide; Tyr added to N-terminus of hGH 177-191; intramolecular Cys7-Cys14 disulfide bridge	[Peer-reviewed preclinical - Heffernan 2001, PMID 11713213] 🔴
Sequence	H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH (intramolecular S-S bridge Cys7-Cys14)	[Academic secondary source - PubChem CID 71300630]
CAS (free base)	386264-39-7	[Academic secondary source - PubChem; Regulatory document - FDA PCAC briefing]
CAS conflation	221231-10-3 widely used by vendors for AOD-9604 AND HGH Fragment 176-191 - disambiguation required	Vendor cross-check [flagged]
Molecular formula	C₇₈H₁₂₃N₂₃O₂₃S₂	[Academic secondary source - PubChem CID 71300630]
Molecular weight	~1815.1 g/mol (free base)	[Academic secondary source - PubChem]
UNII	7UP768IP4M	[Regulatory database - NIH GSRS]
Class	Synthetic hGH C-terminal fragment analogue (growth hormone fragment)	[Regulatory document - WADA 2026 Prohibited List S2.2.3]
Brand names	None (no approved drug product anywhere)	[null finding - FDA/EMA/MHRA/PMDA/NMPA/MFDS/TGA/Health Canada/GRLS inventories]
Aliases	Tyr-hGH(177-191); Tyr-(177-191)hGH; “Advanced Obesity Drug 9604”; informally “AOD”	[Peer-reviewed - Stier 2013] ⚠️

---

2. History and Development

AOD-9604 was identified and characterised in the 1990s by Professor Frank M. Ng and colleagues at Monash University, Melbourne, with the goal of isolating the lipolytic activity of human growth hormone from its mitogenic and diabetogenic activities. 🔴 [Peer-reviewed preclinical - Ng 2000, PMID 11146367] Commercialised by Metabolic Pharmaceuticals Ltd (ASX-listed; ticker MBP), which progressed AOD-9604 through six human studies and reached a peak market capitalisation of ~A$500 million. ⚠️

Development timeline:

• 2000-2001: Foundational preclinical publications (Ng 2000; Heffernan 2000, 2001). 🔴
• December 2004: Phase 2b OBESE study, n~300, oral, 12-week. The 1 mg arm produced 2.8 kg mean weight loss vs 0.8 kg placebo at 12 weeks (verbatim figure carried in Stier 2013). ⚠️
• 2005-2007: Phase 2b OPTIONS study, n=536 enrolled, 24-week design with primary endpoint at 12 weeks; doses 0.25, 0.5, 1 mg/day vs placebo with intensive diet/exercise. ⚠️
• March 2007: Metabolic terminates development; OPTIONS missed its primary weight-loss endpoint. ⚠️
• 2009: Metabolic Pharmaceuticals renamed Calzada Limited.
• 2013: Stier, Vos, Kenley publish AOD-9604 human safety synthesis in J Endocrinol Metab. ⚠️
• 2013-2014: GRAS notification submitted (GRN 000429, food-ingredient use only).
• 2014: Calzada renamed PolyNovo Limited.
• 30 April 2015: PolyNovo divests AOD-9604 IP to Lateral Pharma Pty Ltd (founded by former Metabolic CEO David Kenley) for A$1.5M upfront plus royalty/milestone structure; Lateral targeting osteoarthritis as the lead indication.
• 2015: Kwon et al. publish rabbit-model intra-articular AOD-9604+HA OA paper (PMID 26275694).
• 29 September 2023: FDA places AOD-9604 (alongside BPC-157, TB-500, CJC-1295, ipamorelin and 14 others) into Category 2 of the interim 503A bulks list.
• 20 September 2024: FDA removes AOD-9604 from Category 2 (effective 27 Sep 2024) following nominator withdrawal. [Regulatory document - Federal Register FR Doc 2024-21241]
• 4 December 2024: PCAC reviews AOD-9604 (free base and acetate); unanimous 12-0 against placement on the 503A Bulks List. [Regulatory document - FDA PCAC Final Summary Minutes]
• 2025-2026: No revived Lateral Pharma OA trial in ANZCTR, ClinicalTrials.gov or EU CTR public records as of May 2026.

Australian sport-supplement scandal context: AOD-9604 featured in the 2012-2013 Essendon Football Club supplements saga and the parallel Cronulla Sharks NRL case. Essendon self-reported supplement practices to the AFL and ASADA on 5 February 2013; in August 2013 the AFL fined the club A$2 million and barred it from the 2013 finals series, with the principal regulatory finding centred on thymosin beta-4 rather than AOD-9604 (which was not explicitly named in WADA S2 in 2013 and fell under WADA’s S0 “non-approved substance” catch-all per the 22 April 2013 WADA statement). Essendon captain Jobe Watson publicly acknowledged AOD-9604 administration on Fox Footy’s “On the Couch” on 24 June 2013; 34 players were suspended for two years by the Court of Arbitration for Sport on 12 January 2016. The Essendon scandal is the single most-cited cultural reference point for AOD-9604 in Australian press and forums.

---

3. Mechanism of Action

Demonstrated in humans

• No elevation of serum IGF-1 following oral AOD-9604 administration in obese subjects. [Peer-reviewed - Stier 2013] ⚠️
• No detectable anti-AOD-9604 antibodies in the subset of subjects assayed across the six Metabolic-sponsored trials. [Peer-reviewed - Stier 2013] ⚠️
• No adverse effect on oral glucose tolerance in human studies, in contrast to recombinant hGH which impairs carbohydrate handling. [Peer-reviewed - Stier 2013] ⚠️
• Short plasma half-life (~3 minutes after IV; near-complete clearance from plasma by ~12 minutes post-IV). [Peer-reviewed - Stier 2013] ⚠️

The downstream lipolytic mechanism in humans has not been demonstrated directly with isotopic tracer or microdialysis studies in published peer-reviewed literature. Human surrogate endpoints (body weight) are the closest available.

Proposed / preclinical

• In obese Zucker rats, chronic oral AOD-9604 at 500 µg/kg for 19 days reduced body-weight gain >50% (15.8 ± 0.6 g vs 35.6 ± 0.8 g vs control) with increased adipose-tissue lipolytic activity and no insulin-sensitivity decrement on euglycemic clamp. [Peer-reviewed preclinical - Ng 2000] 🔴
• AOD-9604 increased beta-3-adrenoreceptor (beta-3-AR) mRNA expression in obese-mouse adipose tissue back toward lean-mouse levels. [Peer-reviewed preclinical - Heffernan 2001] 🔴
• In beta-3-AR knockout mice, chronic AOD-9604 failed to produce the weight reduction and lipolysis observed in wild-type animals, although acute increases in energy expenditure and fat oxidation persisted - suggesting beta-3-AR is required for the chronic lipolytic phenotype but not for all acute metabolic effects. [Peer-reviewed preclinical - Heffernan 2001] 🔴
• Rabbit collagenase-induced knee OA: intra-articular AOD-9604 + HA produced lower gross and histopathological cartilage damage scores than HA or AOD-9604 alone. [Peer-reviewed preclinical - Kwon 2015]

Not demonstrated / common overclaims

• AOD-9604 is not demonstrated to bind the canonical somatotropin (GH) receptor with high affinity; it lacks GH “binding site 2” required for GHR dimerisation.
• “GH-mimetic effects without IGF-1” overstates the evidence: IGF-1 neutrality is established, but direct demonstration of human lipolysis beyond surrogate body-weight endpoints is absent.
• “Selective beta-3-AR agonism” mischaracterises the preclinical signal: AOD-9604 modulates beta-3-AR expression and acts via beta-3-AR-dependent and beta-3-AR-independent pathways in mice; it is not a beta-3-AR agonist in the classical pharmacological sense. r/Peptides 1ldr0oz (2025-06-17) extends this confusion into community SNP/genetic-non-responder theorising.

---

4. Regulatory Status

4.1 Drug-regulatory status

Authority	Status	Source
FDA (US)	Not approved as a drug for any indication. GRAS food-ingredient determination only.	[Regulatory document - FDA]
FDA - 503A interim list	Was Category 2 (significant safety risks); moved off Category 2 on 2024-09-20 (effective 2024-09-27) following nominator withdrawal; PCAC reviewed 2024-12-04.	[Regulatory document - Federal Register FR 2024-21241]
FDA - PCAC vote 2024-12-04	Unanimous against placement on 503A Bulks List: AOD-9604 free base AND acetate - single combined vote, Yes 0 / No 12 / Abstain 0.	[Regulatory document - FDA Final Summary Minutes, fda.gov/media/185642]
FDA GRAS	GRAS Notice GRN 000429 (Metabolic Pharmaceuticals), FDA “no questions” response - food-ingredient use only at ~1 mg/day. Not a drug approval.	[Regulatory database - FDA GRAS Notice Inventory]
EMA	Not approved. No CHMP scientific opinions located.	—
MHRA (UK)	Not approved.	—
PMDA (Japan)	Not approved.	—
NMPA (China)	Not approved.	—
MFDS (S. Korea)	Not approved.	—
TGA (Australia)	Not registered on the ARTG as a finished medicine; AOD-9604 captured in Schedule 4 (Prescription Only Medicine) of the Poisons Standard under human growth hormone analogues/fragments.	[Regulatory document - TGA Poisons Standard]
Health Canada	Not approved; listed as unauthorised.	—
GRLS (Russia)	Not approved.	—
WHO EML	Not listed.	—

PCAC 4 December 2024 - FDA briefing concerns (Drs Kneeream and Mathew presentations; Topic transcript at fda.gov/media/185641):

1. “AOD-9604 free base is not well characterized due to lack of certain critical characterization data… potential immunogenicity risk when formulated in an injectable dosage form for subcutaneous administration; and lack of information on critical attributes associated with other proposed pharmaceutical dosage forms such as transdermal cream and oral capsule.”
2. The submitted Certificate of Analysis controlled for identity, peptide purity, water content and assay, but “Testing results for the control on impurities, aggregates, bioburden, and bacterial endotoxins were not included.”
3. The intramolecular disulfide (Cys7-Cys14) flagged as a stability/degradation vector.
4. FAERS/CAERS searches returned no reports - FDA treated this as inability to characterise safety, not evidence of safety.
5. The pivotal Phase 2b OPTIONS study (~502 evaluable) failed its primary weight-loss endpoint; development terminated 2007. The compound’s own public-hearing advocate, Edwin Lee MD FACE, conceded that AOD-9604 should not be considered a weight-loss peptide and argued instead for safety/regenerative applications - an admission that aligned with the FDA recommendation.

Enforcement: A series of FDA Warning Letters issued in late 2024 targeted online sellers of compounded / research-labelled peptides marketed for human use. The Frier Levitt enforcement summary names AOD-9604 alongside ipamorelin, BPC-157, CJC-1295 and kisspeptin-10 as commonly cited substances, with violations alleged under FDCA §§ 505(a) and 301(d) (misbranding / unapproved new drug).

4.2 Anti-doping status

WADA 2026 Prohibited List (effective 2026-01-01): AOD-9604 is explicitly named under section S2.2.3 - GROWTH HORMONE (GH), ITS ANALOGUES AND FRAGMENTS, INCLUDING, BUT NOT LIMITED TO: … growth hormone fragments, e.g. AOD-9604 and hGH 176-191. [Regulatory document - WADA 2026 Prohibited List, wada-ama.org]

• Status: Prohibited at all times (in- and out-of-competition).
• Specification: Non-Specified.
• TUE eligibility: Not eligible - no approved therapeutic indication in any jurisdiction.
• USADA: Prohibited at all times via incorporation of the WADA list.
• NCAA: Prohibited under peptide hormones/growth factors class.
• DoD-OPSS: Listed as prohibited for U.S. military personnel.
• Global DRO: Returns “prohibited at all times” across all listed sports/countries.
• BSCG: Listed among growth-hormone fragments tested in supplement certification.
• VADA 2026: Mirrors WADA S2.2.3 with AOD-9604 explicitly named.

Documented sanctions: AOD-9604 featured prominently in the 2012-2013 Essendon/Cronulla sport-supplement scandals, though the CAS 2016 guilty finding centred on thymosin beta-4. Routine anti-doping detection assays for AOD-9604 are not standardised across all WADA labs as of May 2026; ELISA / LC-MS methods for growth-hormone fragments are an active development area.

4.3 Last regulatory review

Last regulatory review: 2026-05-20

---

5. Formulations and Routes

Route	Status	Notes
Oral capsule / tablet	Investigational (programme discontinued 2007)	Metabolic clinical programme used a proprietary oral formulation; rapid degradation and very low oral bioavailability characterised by Stier 2013. ⚠️
Intravenous	Investigational (Phase 1 only)	METAOD001 (n=15) and METAOD002 (n=23) pilot safety studies; ~3 min plasma half-life. ⚠️
Subcutaneous (compounded grey-market)	Not approved anywhere	FDA briefing flagged immunogenicity risk for SC delivery without rigorous impurity / aggregate / endotoxin controls. The dominant grey-market route. Reconstitution-gelling is a community-documented handling issue (r/Peptides 13qz0jc, 1moij72); community workaround is ~0.5 mL 5% white vinegar or dilute acetic acid to dissolve the disulfide-bridged peptide.
Transdermal cream	Proposed in 503A nomination; FDA noted absent CoA detail; not approved	Cosmetic anti-cellulite programme deprioritised by 2007. Persists in scattered medspa offerings.
Intra-articular	Preclinical only (rabbit OA model, Kwon 2015)	No human IA studies published. Tailor Made Compounding “AOD 9604 + HA” SKU is the canonical community product.
Intranasal	Sold by research-chemical vendors; no published PK or efficacy data	Community signal uniformly negative (“bunk”; AnabolicMinds; r/Peptides mgjzjt).
Topical anti-cellulite cosmetic	Original Metabolic programme deprioritised by 2007	No current TGA AICIS / EU CPNP / FDA cosmetic notification for AOD-9604 located.

Peptide-impurity concerns specific to AOD-9604 (FDA PCAC 2024-12-04 briefing): synthetic peptides can carry sequence-related impurities (deletion, insertion, oxidation, racemisation), aggregates, process-related impurities and endotoxins; impurities sharing partial sequence with the parent peptide can drive immunogenic responses cross-reactive with endogenous targets. The AOD-9604 nomination did not include adequate aggregate or endotoxin testing data.

---

6. Preclinical Evidence

Status label: all preclinical; rodent and rabbit models - direct translation to human metabolic outcomes is not established.

• Ng 2000 (Hormone Research; PMID 11146367) - obese Zucker rats, oral AOD-9604 500 µg/kg × 19 days reduced body-weight gain >50%, increased adipose lipolytic activity, no insulin-sensitivity decrement. 🔴
• Heffernan 2000 (Am J Physiol Endocrinol Metab; PMID 10977661) - oral hGH C-terminal fragment lipid-metabolism effects in mice. 🔴
• Heffernan 2001 (Endocrinology; PMID 11713213) - obese-mouse and beta-3-AR knockout-mouse experiments; beta-3-AR required for chronic but not acute effects; AOD-9604 restores beta-3-AR mRNA in obese mice. 🔴
• Kwon 2015 (Ann Clin Lab Sci; PMID 26275694) - collagenase-induced rabbit knee OA; intra-articular AOD-9604 + HA combination superior to either alone on gross morphology and histopathology.
• Carcinogenicity / genotoxicity package supporting the GRAS submission (More 2014, J Endocrinol Metab): negative Ames, negative chromosomal aberration, negative bone-marrow micronucleus; chronic oral toxicology in rats and cynomolgus monkeys without genotoxic or systemic toxicity signals. ⚠️

Rodent-to-human translation caveats: murine beta-3-AR pharmacology differs substantially from human beta-3-AR pharmacology (selective beta-3-AR agonists such as CL-316,243 produce robust rodent weight loss without translating to comparable human effects). The collagenase-induced rabbit model is a structural OA model, not a chronic, slowly progressive disease analogue.

---

7. Clinical Evidence

7.1 Cochrane / systematic reviews

A targeted search of the Cochrane Library returns no Cochrane systematic review of AOD-9604 for obesity, body composition, osteoarthritis, cosmetic dermatology, or any other indication as of May 2026. [Cochrane Library - null finding] No PRISMA-grade systematic review or meta-analysis of AOD-9604 in any indication was identified in PubMed, Scopus or Embase. The Stier 2013 / More 2014 J Endocrinol Metab papers are the principal synthesis of the six Metabolic-sponsored trials; they are author-published company syntheses, not independent systematic reviews. ⚠️

7.2 Randomized controlled trials

All six human studies were sponsored by Metabolic Pharmaceuticals Ltd. ⚠️ industry-funded across the entire RCT base; all trace to the Ng/Heffernan/Monash research group 🔴.

Study	Phase	n	Route	Dose	Duration	Result	Source
METAOD001	Phase 1 IV	15 healthy male BMI 24-30	IV	25-400 µg/kg single	Single dose	Safety; positive control rhGH 0.12 IU/kg	Stier 2013 ⚠️
METAOD002	Phase 2a IV	23 obese male BMI ≥35	IV	25, 50, 100 µg/kg	4×4 Latin square	Safety; no IGF-1 effect	Stier 2013 ⚠️
METAOD003	Phase 2a oral	~36	Oral	dose-finding	Pilot	Oral PK; reference data	Stier 2013 ⚠️
METAOD004	Phase 2a oral	~70	Oral	up to 1 mg/day	12 weeks	~2 kg loss > placebo	Herd 2005 ⚠️
METAOD005 (OBESE)	Phase 2b	~300	Oral	1, 5, 10, 20, 30 mg + placebo	12 weeks	1 mg arm: 2.8 kg vs 0.8 kg placebo	Metabolic ASX Dec 2004 ⚠️
METAOD006 (OPTIONS)	Phase 2b	536 enrolled / ~502 evaluable	Oral	0.25, 0.5, 1 mg + placebo, intensive diet/exercise	24 wk (primary at 12 wk)	Primary endpoint missed - no statistically significant weight loss above placebo + diet + exercise. Development terminated.	Metabolic ASX 2007 ⚠️

Publication status: the most rigorous search of PubMed, Scopus and Embase locates only one peer-reviewed indexed publication directly reporting Phase 2 efficacy data: the Herd et al. 2005 Obesity Research NAASO meeting abstract. No standalone, full-length, peer-reviewed primary publication of the OPTIONS Phase 2b results (n=536) exists in indexed journals. The data exist as (a) the March 2007 ASX/SEC announcement; (b) re-tabulated summaries in Stier 2013 and More 2014; (c) the FDA PCAC briefing’s secondary citation. This is a substantive evidence-quality limitation.

7.3 Observational / real-world evidence

A docket submission from compounding-pharmacy advocates to PCAC (FDA-2024-N-4777-0009 attachment 4) referenced “158,989 prescriptions” of AOD-9604 from compounding-pharmacy records with self-reported tolerability; this is a self-selected, uncontrolled pharmacy dataset, not peer-reviewed real-world evidence. No prospective registry-based real-world cohort study of AOD-9604 was located in PubMed.

7.4 Trial registry / active programs

Targeted searches of ClinicalTrials.gov, EU CTR, ANZCTR and WHO ICTRP for “AOD9604” / “AOD-9604” / “Tyr-hGH” returned no actively recruiting or recently completed (2020-2026) trials as of May 2026. The 2015 PolyNovo divestiture to Lateral Pharma signalled an osteoarthritis development plan, but no registered Lateral Pharma trial of AOD-9604 in OA, pain or cartilage repair is publicly listed.

7.5 Disputed Claims

1. AOD-9604 vs HGH Fragment 176-191 identity conflation - extensively documented in commercial channels, with a low-engagement trace example also surfacing at thread level on r/Peptides (1jpjj56, 2025-04-02). The two molecules differ by an N-terminal Tyr substitution and ~16 Da of mass. Treating safety, PK or mechanism data from one as transferable to the other is not scientifically defensible.
2. Beta-3-AR mechanism in humans - established only in rodent models; not directly demonstrated in humans (no human beta-3-AR engagement, lipolysis tracer or microdialysis data published for AOD-9604).
3. “Lipolysis without IGF-1 elevation” marketing claim - IGF-1 neutrality is supported by Stier 2013 human data ⚠️; the lipolysis half is supported only by surrogate (body-weight) endpoints in trials that ultimately failed (OPTIONS).
4. Cartilage / joint-repair efficacy - single peer-reviewed in vivo paper (Kwon 2015, rabbit) plus in vitro chondrocyte patent data. No human RCT.
5. FDA GRAS designation = FDA approval for therapeutic use - the single most-exploited regulatory misframe in medspa/clinic marketing. GRN 000429 covers food-ingredient use at ~1 mg/day only.

---

7B. Community Evidence Layer

Community context

AOD-9604 entered Western optimization-community awareness in two distinct waves. The first wave (2008-2013) was driven by Australian biotech press coverage of Metabolic Pharmaceuticals’ Phase 2b clinical programme and, decisively, by the Essendon Football Club / ASADA supplements scandal of 2012-2013. Sports scientist Stephen Dank’s April 2013 Fairfax Media admission - that Essendon players “were given anti-obesity drug AOD9604” to aid recovery - is the seed quote for the cartilage/recovery framing that still dominates Australian and clinic marketing. The second wave (2021-2025) rode the GLP-1 boom: as semaglutide and tirzepatide became cultural fixtures, US wellness clinics and compounding pharmacies began bundling AOD-9604 troches and SC vials as “non-GLP-1 fat-loss adjuncts” - explicitly marketed as “the safe HGH fragment” that “doesn’t raise IGF-1 or insulin.” Jay Campbell’s “AOD9604 and Semaglutide Stack” blog post (2021-2022) is the most-cited Western biohacker write-up.

Driving subcommunity: general-population weight-loss / wellness-clinic patients - not bodybuilders or longevity hardcores. AOD-9604 is the rare peptide whose centre of gravity is the medspa and the compounding pharmacy, not r/Steroids. Bodybuilder reception has always been lukewarm-to-dismissive.

Trajectory (May 2026): declining-to-niche in the US following the FDA’s September 2023 Category 2 designation and the December 2024 PCAC vote against inclusion. April 2026 announcement of removal from Category 2 for 12 peptides (not AOD-9604) and July 2026 PCAC meetings have created a wait-and-see mood; some clinics still offer the product, others have substituted GLP-1 monotherapy.

Duality of marketing register: AOD-9604 sits in a distinctive respectability halo / underground duality. Wellness MD clinics (Padgett Medical Ocala, Beverly Hills Rejuvenation Center, Perfect B Doral, Gruene Road Pharmacy, American Medical Wellness) market it in scrubs-and-stethoscope register: “FDA GRAS-designated,” “physician-supervised,” “no growth-hormone risks.” Research-chemical vendors (Edge Peptides, Core Peptides, Limitless Life, Peptide Sciences) sell the same compound as a lyophilised “for research use only” vial at $20-55. The FDA GRAS designation - which applies only to food-ingredient use - is the single most-exploited conflation in the clinic marketing copy.

Documented protocols

Source	Date	Dose	Frequency	Cycle	Route	Notes
EliteFitness “AOD 9604 Reconstitute” bodybuilding_archive	2023-01-11/12	300 mcg	Once daily	n/s	SC (Umbrella Labs 5 mg vial reconstituted with 5 mL BAC water -> 1 mg/mL; 0.3 mL draw)	First-experience post; moderator-reviewed
Muscle and Brawn guide bodybuilding_archive	2024 update	300 mcg/day; max 500-600 mcg/day; 20 days on then break	Daily, morning fasted	20-day pulses	SC; nasal spray noted	Standard bodybuilding cutting-phase protocol
Jay Campbell blog biohacker_publication, COI affiliate	2021-2022	300 mcg AOD + escalating semaglutide	Daily AOD, weekly sema	24+ days reported	SC	”FORCE myself to eat just one” burger after fast
Swolverine dosing guide indirect_source	2024	250-500 mcg	Daily	n/s	SC, abdominal, AM	”Most common practice in weight loss clinics”
Padgett Medical Ocala clinic_protocol, COI	2025 access	n/s; troche	Daily, sublingual dissolution	Multi-month	Oral troche	”Slowly dissolved under the tongue… avoiding degradation in the digestive tract”
Age Management of West Michigan clinic_protocol, COI	2025 access	n/s; capsule	Twice daily on empty stomach	12-week cycle	Oral capsule	”Can be used in conjunction with other peptides and hormone therapies”
Tailor Made Compounding catalog vendor_claim, COI	2020 archive	Practitioner-prescribed	Daily	n/a	SC; also AOD 9604 + HA combo for intra-articular joint injection	The HA combo derives from Kwon 2015 rabbit OA study
Peptide Works nasal spray vendor_claim, COI	2025 access	15 mL & 30 mL bottles	Daily intranasal	n/a	Nasal spray	”For research use only” disclaimer
AnabolicMinds “Anyone Ever Heard Of AOD9604?” bodybuilding_archive	Multi-year	”Either bunk or doesn’t work. Save your money imo”	n/a	n/a	Nasal + SC comparison	Negative on both routes
r/Peptides 1lcj57t “My peptide progress” + 1ljzhud “Lab tests are in!” public_forum	2025-06-16, 2025-06-25	AOD-9604 + Tirzepatide + Tesamorelin + Ipamorelin	Daily	6 wk reported	SC	r/Peptides member shares actual bloodwork; 230 → 183 lb over 13 months on multi-stack cut

Route summary: subcutaneous injection is the bodybuilder/biohacker default at 250-500 mcg/day (most often 300 mcg AM). Oral troches and capsules dominate the medspa channel at undisclosed doses, with twice-daily empty-stomach or single sublingual troche the most common pattern. Nasal sprays circulate via research-chem vendors but the community signal on them is uniformly negative. Transdermal creams persist in scattered medspa offerings without protocol detail.

Reconstitution as community knowledge artifact: AOD-9604 reconstitutes poorly in bacteriostatic water alone - r/Peptides 13qz0jc (2023-05-24, score 6, 37 comments) frames it as “using bacteriostatic water alone will result in a foamy particulated solution that won’t inject consistently” and proposes 5% white vinegar in BAC water. r/Peptides 1moij72 (2025-08-12, score 16, 31 comments) documents persistent gelling even with acetic acid added at 2 mL BAC + 0.4 mL AA and 3 mL + 0.6 mL. This is a community-discovered pharmaceutical-handling problem that the published literature does not address - and is consistent with the FDA PCAC briefing’s flag on disulfide-bridge stability.

Claimed effects

• Stubborn / abdominal fat loss - widespread across vendor and clinic copy; occasional in user reports. Top community sources: Jay Campbell semaglutide-stack post (2021-2022); compounding-pharmacy marketing universally claims “accelerated fat-burning, particularly in the abdominal area” (Gruene Road Pharmacy).
• No HGH-like side effects (no IGF-1, no insulin resistance, no glucose disruption) - near-universal community claim, echoing Stier 2013.
• Joint / cartilage repair - common in Australian and US clinic copy; single-source in primary literature (Kwon 2015 rabbit). Tailor Made “AOD 9604 + HA” product. r/Peptides 156jnwo (2023-07-22) member explicitly conflicted about whether the OA application protocol differs from weight-loss protocol.
• Recovery from training / soft-tissue healing - common; the Stephen Dank framing imported into Australian sports-med culture.
• Appetite suppression - single-source-dominant but high-profile; Jay Campbell. Note: contradicts science-layer claim that AOD-9604 does not act on hunger hormones; plausibly attributable to the semaglutide co-administered in Campbell’s stack.
• “Spot reduction” at injection site - occasional in TikTok/medspa influencer content; not in the primary literature. r/Peptides 1kb0j06 (2025-04-29) records a community member starting AOD-9604 specifically for double-chin reduction.
• Euphoric / antidepressant effect (IV route, historical) - single-source; Prof Gary Wittert told Australian press in 2013 that intravenous administration produced euphoria in “60 per cent of people,” leading him and Metabolic to patent an antidepressant indication. A forgotten historical claim.
• Anti-cellulite (topical) - historical-only; Metabolic-licensed cosmetic cream “dropped due to high costs and ineffectiveness” (Mr Supplement Australia).

Reported side effects

• “Felt nothing” / placebo-tier response - the single most consistent community signal. r/Peptides 1phsd5j “Is AOD actually doing anything for you guys” (2025-12-08, score 26, 14 comments): “I’ve been running AOD-9604 for about 5 weeks now… I just added AOD hoping it would give me a slight push. If you’ve run it longer, did you actually notice a difference? Or is AOD one of those peptides…” AnabolicMinds: “Save your money imo.” This is by far the dominant lived-experience report and is the defining note of the AOD-9604 community profile.
• Injection-site reactions (redness, swelling, mild discomfort) - occasional; American Medical Wellness clinic page acknowledges “mild injection-site reactions.”
• Headache - occasional; Beverly Hills Rejuvenation Center cites it as “most commonly reported” but notes incidence was indistinguishable from placebo in trials.
• Mild GI upset (oral troche / capsule) - occasional; Swolverine dosing guide.
• No IGF-1 / no glucose effect - near-universal community claim, consistent with Stier 2013.
• Zero immunogenicity / antibody formation - single-source (the Metabolic Pharma trials), cited downstream by clinics. Note that the FDA PCAC briefing reframes this as inability-to-characterise rather than safety evidence given absent aggregate/endotoxin data.
• Reconstitution gelling - common on grey-market subcutaneous use; community has improvised acetic-acid workaround.

Community dissent

The dissent register on AOD-9604 is unusually loud and converges on several stable positions:

1. “AOD9604 is just expensive placebo.” Anchoring source: AnabolicMinds thread. Reinforced by Mr Supplement Australia: “Six human clinical trials, however, revealed no weight loss or changes in body composition.” The dominant lived-experience signal in the 1311-record Reddit inventory.
2. “What you’re sold as ‘AOD9604’ is probably HGH Frag 176-191.” Eroids 2022 AOD-vs-HGH-Frag identity thread; r/Peptides 1jpjj56 (2025-04-02, trace signal only). Several vendor pages (Pure Health, Peptide Pro, Behemoth Labz) explicitly equate the two compounds, supporting the suspicion. The central QC concern for AOD-9604 grey-market supply.
3. “Oral / transdermal / nasal versions don’t absorb.” AnabolicMinds: “Either bunk or doesn’t work.” Meto blog: “absorption rates vary and results can be inconsistent.”
4. “The Essendon scandal proves it doesn’t work.” Prof Gary Wittert: “no clinical evidence that it helped with tissue repair or had any other benefit in people.” The CAS 2016 guilty finding centred on thymosin beta-4, not AOD-9604 - implicitly conceding AOD-9604 was not meaningfully performance-enhancing.
5. “Compounding pharmacies / medspas are scamming consumers.” FDA’s September 2023 Category 2 designation, December 2024 PCAC vote, and the ongoing FDA Warning Letter cadence form an institutional dissent narrative. Wellness clinics selling troches at $150-400/month on the GRAS-equals-FDA-approved conflation are the canonical example.
6. “Why doesn’t it work for me?” r/Peptides 1ldr0oz (2025-06-17) proposes a SNP-based “check your beta-3-AR variants” framework as a community explanation for non-response. Framed as working theory rather than established pharmacology.

Stack patterns

• AOD-9604 + semaglutide / tirzepatide - most common 2024-2026 stack; explicit clinic marketing (Colorado Medical Solutions, Mobile Care Health, LIVV Natural, Padgett Medical Ocala, Jay Campbell). r/Peptides 13wdit6 (2023-05-31), r/Peptides 1ljzhud (2025-06-25). Rationale: GLP-1 handles appetite/intake; AOD handles fat-tissue signaling. Meto blog cautions there is “no robust, high-quality human outcomes literature showing that adding AOD-9604 to semaglutide or tirzepatide produces clinically meaningful additional fat loss.”
• AOD-9604 + CJC-1295 / Ipamorelin - common in clinic protocols; marketed as “fat-burn + GH pulse” combo. r/Peptides rqyfqm (2021-12-29) compares CJC/Ipa+Tesa stack directly against AOD-9604 for fat loss.
• AOD-9604 + Tesamorelin - occasional; visceral-fat-stack framing. r/Peptides 1lcj57t / 1ljzhud (2025-06) document concurrent use in a full stack.
• AOD-9604 + L-carnitine / T3 / NAD+ - common in TikTok creator content.
• AOD-9604 + HA (hyaluronic acid), intra-articular - niche but documented; Tailor Made’s “AOD 9604 + HA” SKU.
• AOD-9604 + BPC-157 / TB-500 - occasional; recovery/joint stack framing imported from the Essendon-era protocol.
• AOD-9604 + HGH itself - rare; community generally treats AOD as a “no-IGF-1 alternative to HGH,” not a co-administered adjunct.

Vendor / supply context

Research-chemical channel (2025-2026 pricing snapshot for 5 mg vials, single-unit):

• Edge Peptides: $315 / 10-vial box (50 mg total) = $31.50/vial. ⚠️ COI
• Limitless Life (Limitless Biotech): $52.79 single vial (often listed out-of-stock post-FDA action). ⚠️ COI
• Peptide Sciences: 6 mg vial, price gated. ⚠️ COI
• Core Peptides, Biotech Peptides, Pure Health Peptides, Peptide Crafters, Iron Mountain Labz, Simple Peptide, Liberty Peptides: 5 mg vials in the $20-50 single, $200-315 10-pack range. ⚠️ COI
• Elite Lab Peptides: tiered $19.99 / $24.99 / $34.99 SKUs. ⚠️ COI

COA practice: HPLC purity claims typically ≥98-99%; mass-spectrometry identity confirmation claimed but rarely posted batch-by-batch. Independent third-party testing (Janoshik Analytical) of AOD-9604 batches occasionally referenced in community threads but not systematically indexed.

Compounding pharmacy channel (US, distinctive AOD-9604 dimension): the pre-2023 landscape included Tailor Made Compounding (Kentucky), Empower Pharmacy (Texas), AnazaoHealth, BioPharma, Strive Pharmacy, Olympia Pharmacy and dozens of smaller 503A pharmacies serving wellness clinics with subcutaneous AOD-9604, oral troches, sublingual lozenges and (less frequently) transdermal creams. Post-September 2023, FDA Category 2 placement effectively halted bulk compounding via 503A; the September 2024 procedural removal (nominator withdrawal) and December 2024 PCAC vote against inclusion mean the compound currently sits in regulatory limbo. Some clinics still appear to offer it, others have substituted GLP-1 monotherapy.

Marketing register across the compounding-pharmacy channel is remarkably consistent: “Safe, targeted fat-loss peptide” / “no growth-hormone side effects” / “FDA-GRAS designation” cited as quasi-approval / “Doesn’t raise IGF-1 or impair insulin sensitivity” / troche price points $150-400/month-equivalent.

QC issues, scandals, mislabeling:

• AOD-9604 vs HGH Frag 176-191 mislabeling - the central commercial conflation. Pure Health Peptides, Behemoth Labz and Peptide Pro vendor pages explicitly treat them as the “same compound.”
• Nasal-spray bunk reports - AnabolicMinds documents two consecutive nasal-spray bottles from “amino depot” with zero effect.
• Australia / US / international split - Australia: AOD-9604 requires a prescription (TGA Appendix D), dispensed through compounding pharmacies. Canada and the EU: unauthorized. US: grey-market split (research-chem + medspa) is unique.

Community Score / Tier

Component	Score (max 25)	Rationale
Usage volume	16 / 25	Moderate. Real presence in US medspa / compounding-pharmacy / telehealth weight-loss channels and via 10+ research-chem vendors. Not in the top tier (BPC-157, semaglutide, CJC/Ipa). FDA Category-2 sweep dented availability. 1311-record Reddit inventory dominated by r/Peptides (n=1239) confirms moderate but not heavy footprint.
Protocol codification	18 / 25	Reasonably settled for injectable (300 mcg/day AM, SC, 8-24 wk). Oral/troche/cream dosing remains opaque and varies by clinic. Nasal-spray protocol is non-credible. Reconstitution-gelling problem is acknowledged at community level but vendor handling protocols are inconsistent.
Reported effect consistency	9 / 25	Low. The “felt nothing” signal is itself extremely consistent - which hurts the score. Trial data (negative METAOD006 efficacy) corroborates user skepticism. Positive reports concentrated in vendor-affiliated copy. r/Peptides 1phsd5j (2025-12-08) is the most recent published-in-community confirmation of the dominant null signal.
Time in circulation	19 / 25	Long. Patented late 1990s, in human trials by mid-2000s, Essendon-era publicity 2012-2013, second wave 2021-present. ~20+ years of community presence.
TOTAL	62 / 100	Community Tier B (60-74 band)

The 62/B reflects a compound with broad availability, long history, and codified injectable dosing, but unusually weak user-experience consistency and a regulatory cloud. AOD-9604 is a “settled, mostly-disappointing” compound - known, tolerated, doubted.

Retrieval limitations

Reddit evidence was retrieved through Arctic Shift / PullPush with Arctic Shift parent-thread recovery attempted for top thread IDs. Capture is snapshot-based, query-dependent, and skewed toward r/Peptides (n=1239 of 1311 deduped records). Top thread candidates were verified at permalink level by the editor on 2026-05-20. Comment-level records without recovered parent-thread metadata are used only as secondary signal. Cluster tags (claimed_effect, dosing_protocol, stack_combo etc.) are heuristic. These records are community signal only, not efficacy or safety evidence.

The 2026-05-20 Reddit inventory replaces the earlier Pass 2B retrieval limitation that “Reddit primary sources could not be retrieved at named-source resolution in this pass.” Reddit signal is now verified at thread level for r/Peptides. The earlier limitations on compounding-pharmacy gated pricing (Tailor Made, Empower, AnazaoHealth, BioPharma practitioner login), absence of a dedicated Huberman / Attia / Derek MPMD / Tony Huge / Layne Norton episode on AOD-9604, and per-batch COA inspection at vendor pages remain unaddressed.

---

8. Safety Profile

Common adverse events

Across the six Metabolic-sponsored human studies (cumulative exposures cited as ~925 subjects in company communications), AOD-9604 safety and tolerability were reported as indistinguishable from placebo, with no serious adverse event judged related to AOD-9604 and no study withdrawal attributed to the drug. ⚠️ Published adverse-event tables are summary-level only; individual-patient line listings are not in the public peer-reviewed record.

Serious or theoretical risks

• IGF-1 elevation - not observed in human studies (claimed absent). ⚠️
• Immunogenicity - flagged by FDA PCAC 2024-12-04 briefing as a theoretical risk when AOD-9604 is delivered subcutaneously without rigorous impurity/aggregate/endotoxin controls; peptide-related impurities and process contaminants can introduce neoepitopes that cross-react with endogenous sequences.
• Peptide-impurity concerns - the 503A nomination CoA did not include aggregate, bioburden or endotoxin testing data.
• Disulfide-bond stability - Cys7-Cys14 bridge is a degradation vector under formulation stress. Consistent with community-observed gelling on reconstitution (r/Peptides 13qz0jc, 1moij72).
• Cardiovascular signal - none reported in clinical trials; no QT/QTc dedicated study.

Trial exclusions / special populations

Phase 2 trials excluded pregnancy and lactation; no paediatric data exist; no data in non-obese adults; no data in moderate-severe renal/hepatic impairment. Older-adult subgroup analyses not published.

Community-reported adverse signals

• Injection-site redness/swelling (occasional, American Medical Wellness).
• Headache (occasional, clinic-reported, indistinguishable from placebo in trials).
• Mild GI upset on oral troche/capsule (Swolverine guide).
• Reconstitution gelling and inconsistent dose delivery (r/Peptides 13qz0jc, 1moij72).
• Predominant signal: no effect.

Pharmacovigilance / regulatory safety communications

• FAERS / CAERS searches (through July 2024, per FDA PCAC briefing): no AE reports retrieved; FDA treated this as inability-to-characterise rather than evidence of safety.
• FDA Warning Letters (late 2024-): series of letters to online peptide sellers marketing AOD-9604 for human use as misbranded / unapproved new drugs.
• TGA communications: Schedule 4 captures AOD-9604; also implicated historically in TGA performance-and-image-enhancing-drugs (PIEDs) commentary surrounding Australian sport supplement scandals (2013-).

---

9. Drug Interactions

No clinically documented drug-drug interactions for AOD-9604 are reported in peer-reviewed literature or in any regulatory product information (none exists). Absence of data does not equal absence of interaction. Theoretical interactions of interest - given the proposed metabolic pathway and the absence of dedicated studies - include agents acting on beta-adrenergic signalling (beta-agonists, beta-blockers), agents altering carbohydrate handling (insulin secretagogues, GLP-1 receptor agonists, SGLT2 inhibitors), and other GH-axis modulators (somatropin, tesamorelin, GH secretagogues). These remain conjectural until tested.

Community stacking patterns most likely to produce confounded outcomes are the AOD + semaglutide / tirzepatide combination (where the GLP-1 RA drives the observed effect; AOD’s contribution is not isolable) and the AOD + tesamorelin + ipamorelin stack (where the GH-axis component complicates the “no IGF-1 elevation” claim). r/Peptides 1ljzhud (2025-06-25) is an example of a multi-peptide bloodwork share where AOD-9604 cannot be cleanly attributed credit or blame.

---

10. Research Gaps

1. Phase 3 never initiated; programme abandoned for obesity in 2007.
2. Long-term human safety beyond 24 weeks is unknown; immunogenicity, off-target receptor effects, malignancy signals over multi-year exposure have not been characterised.
3. Mechanism not definitively established in humans - no human beta-3-AR engagement, lipolysis tracer or microdialysis data published.
4. No head-to-head comparisons vs GLP-1 receptor agonists, vs tesamorelin (the only FDA-approved GH-axis fat-reduction agent), or vs HGH Fragment 176-191.
5. No data in non-obese populations (athletic body-recomposition use is entirely extrapolative).
6. No controlled cosmetic / topical efficacy data despite a topical anti-cellulite history and current grey-market topical positioning.
7. No human osteoarthritis or cartilage-repair RCT; the Lateral Pharma 2015 IP acquisition has not produced a registered clinical programme that is publicly discoverable.
8. Subcutaneous PK and immunogenicity - the dominant grey-market route - are not characterised in peer-reviewed literature; the Metabolic clinical programme was overwhelmingly oral with limited IV pilot data.
9. Analytical detection methodology for AOD-9604 in anti-doping urine/blood samples is not yet harmonised across WADA labs.
10. No independent (non-Metabolic-network) replication of any AOD-9604 finding in humans. All six trials trace to the Ng/Heffernan/Monash group 🔴.

---

11. Bottom-Line Encyclopedia Note

AOD-9604 is a synthetic 16-residue analogue of the C-terminal lipolytic domain of human growth hormone, distinguished from HGH Fragment 176-191 by an added N-terminal tyrosine. Across six industry-sponsored trials, it produced a placebo-like safety profile and no IGF-1 elevation, but failed its primary weight-loss endpoint in the pivotal Phase 2b OPTIONS study (2007), after which Metabolic Pharmaceuticals terminated development. The FDA’s Pharmacy Compounding Advisory Committee voted unanimously (12-0) against placing AOD-9604 on the 503A bulks list on 4 December 2024, citing inadequate impurity characterisation, immunogenicity risk in injectable form, and absent demonstrated effectiveness. WADA 2026 places AOD-9604 in section S2.2.3 (growth hormone analogues and fragments) - prohibited at all times. No approval exists in any jurisdiction. FDA GRAS Notice GRN 000429 covers food-ingredient use only and is not a drug approval. The 1311-record May 2026 Reddit inventory confirms a 20+ year community presence with a dominant lived-experience signal of non-response.

---

11B. Gap Analysis - Where Science and Community Diverge

Primary gap-matrix pattern: High community + Low science: tested negative or mixed. This is the rare case in this catalogue where a Phase 2b RCT was actually run, against the exact claim the community uses the compound for, and failed. It is not BPC-157’s “untested” pattern; it is closer to ipamorelin’s “indication divergence” pattern but cleaner because no other indication has compensating positive evidence.

Secondary subclass: identity-conflation (AOD-9604 vs HGH Fragment 176-191) - structurally distinct molecules sold under interchangeable names, the central QC problem.

Tertiary subclass: single-group dependency 🔴 - all six human trials sponsored by Metabolic Pharmaceuticals and derived from the Ng/Heffernan/Monash research group. Calibration anchor for this pattern is BPC-157 (Sikiric group); methodologically equivalent here.

Science-community delta:

Dimension	Science layer	Community layer	Delta
Best-supported efficacy claim	None at clinically meaningful effect size	Stubborn / abdominal fat loss; recovery; “no IGF-1” safety	Community holds claims that the failed pivotal trial does not support
Dose	Oral 1 mg/day (positive OBESE arm) or 0.25-1 mg/day (failed OPTIONS)	SC 250-500 mcg/day (primarily 300 mcg AM); transdermal/troche undisclosed	Route divergence + dose divergence: community route was never in the registration package
Regulatory standing	Not approved anywhere; PCAC 12-0 no-vote; WADA explicit	”FDA GRAS-designated” framed as quasi-approval by clinics	Active misframe of regulatory status
Identity	Tyr-hGH(177-191), distinct from HGH Frag 176-191	Vendors equate the two	Identity collapse not present at science layer
Mechanism	Lipolysis pathway unproven in humans; beta-3-AR mRNA modulation in mice	”Selective beta-3-AR agonist” / “tells your body to release fat”	Community simplification overstates mechanism
Effect size	OBESE: 2.8 vs 0.8 kg at 12 wk (trivial vs semaglutide 14.9% / tirzepatide 20.9%)	“Felt nothing” is the dominant signal; positive reports concentrated in vendor copy	Community lived experience aligns with the failed-trial outcome, not with the clinic marketing

Dose-translation note: the research dose was oral 1 mg/day; the dominant community dose is SC 300 mcg/day (=0.3 mg). This is a route swap that breaks the dose-translation comparison entirely. SC PK was never characterised in the Metabolic clinical programme. The FDA PCAC flagged this exact gap as a reason for the no-vote: SC delivery introduces immunogenicity risk without supporting data, and no efficacy data exist for the SC route at any dose. evidence_flags: [dose_translation_unclear, route_dependent_evidence]

The defining unusual feature of AOD-9604 is that the Phase 2b failure is not contested at the science layer - even the compound’s own public-hearing advocate, Edwin Lee MD FACE, conceded at PCAC that AOD-9604 should not be considered a weight-loss peptide. The community-vs-science gap here is therefore not “science doesn’t know yet”; it is “science says no, community says maybe.” The 1311-record May 2026 Reddit inventory increasingly says no as well: the freshest high-signal thread (r/Peptides 1phsd5j, 2025-12-08, score 26) is a published-in-community confirmation that the lived-experience signal matches the failed-trial result.

---

12. Three Paths

Conservative path

Define gates explicitly: an additional independent (non-Metabolic-network) Phase 2 efficacy trial in obesity meeting a clinically meaningful weight-loss endpoint; an FDA, EMA or MHRA approval for any AOD-9604 indication; a regulatory-grade SC pharmacokinetics and immunogenicity dataset; a published human RCT in cartilage / OA. Until those gates are met, AOD-9604 sits below the threshold for serious consideration as an optimization peptide. Conservative-path users would not engage with grey-market AOD-9604 at all.

Moderate path

Treat AOD-9604 as a Tier D / Tier B compound with active regulatory cloud. Baseline characterisation before any use: IGF-1, fasting glucose, HbA1c, full lipid panel, hsCRP, liver and kidney panels, plus DXA or accurate body-composition imaging to establish a measurable endpoint. Use the lowest dose with any published support (oral 1 mg/day, OBESE-positive arm; SC dose has no supporting evidence). Monitor cadence: bloodwork at 6 and 12 weeks. Document supply chain (vendor, COA batch ID, independent third-party assay where feasible) and treat HGH Fragment 176-191 substitution as the default identity risk. WADA-tested athletes: do not use; explicit S2.2.3 prohibition.

High-tolerance path

The community pattern, with mitigations: COA inspection at batch level; independent identity confirmation via Janoshik or equivalent (HPLC + mass spec, with mass spec specifically to distinguish AOD-9604 from HGH Frag 176-191 at the ~16 Da delta); sterility / endotoxin assurance (most grey-market vials do not document this); slow titration; SC 300 mcg/day morning fasted as the codified community dose; reconstitution with weak acid (community-discovered method) rather than BAC water alone; explicit duration cap (8-12 weeks per cycle) given absent long-term safety data; bloodwork before and after each cycle; physician discussion documented. Stack management: avoid stacking AOD with any other compound that prevents attribution of effect to AOD specifically. The most important community-mitigation step here is the identity verification - the AOD-9604 / HGH Fragment 176-191 substitution problem is the single most consequential QC issue and is solvable by mass-spec confirmation.

---

13. Key References

Science layer

Peer-reviewed preclinical:

• Ng FM et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000;53(6):274-278. PMID 11146367. 🔴
• Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab 2000;279(3):E501-E507. PMID 10977661. 🔴
• Heffernan M et al. Effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta-3-AR knock-out mice. Endocrinology 2001;142(12):5182-5189. PMID 11713213. 🔴
• Kwon DR, Park GY, Lee SC. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci 2015;45(4):426-432. PMID 26275694.

Peer-reviewed human safety synthesis (industry-funded):

• Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab 2013;3(1-2):7-15. ⚠️
• More MI, Freitas U, Rutenberg D. Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. J Endocrinol Metab 2014;4(3):64-77. ⚠️

Conference abstract (industry):

• Herd C et al. The effect of AOD9604 on weight loss in obese adults: results of a randomized, double-blind, placebo-controlled, multicenter study. Obesity Research 2005 (NAASO abstract). ⚠️

Regulatory documents:

• FDA. Final Summary Minutes, Pharmacy Compounding Advisory Committee Meeting, 4 December 2024. fda.gov/media/185642/download.
• FDA. PCAC Topic 1 Verbatim Transcript, 4 December 2024 (“A Matter of Record”). fda.gov/media/185641/download.
• FDA. Federal Register notice FR Doc 2024-21241 (18 September 2024).
• FDA. Federal Register notice FR Doc 2024-24828 (25 October 2024).
• FDA. GRAS Notice Inventory, GRN 000429 - AOD9604 (Metabolic Pharmaceuticals).
• WADA. 2026 Prohibited List (effective 1 January 2026), Section S2.2.3.
• VADA. Prohibited List 1-1-2026.
• TGA. Standard for the Uniform Scheduling of Medicines and Poisons (Poisons Standard) - Schedule 4 capture.
• WADA. Statement on substance AOD-9604, 22 April 2013 (historical, S0 classification at that time).

Comparator benchmark (for Science Score effect-size context):

• Wilding JPH et al. STEP-1. NEJM 2021;384:989. (Semaglutide 2.4 mg - 14.9% at 68 wk.)
• Jastreboff AM et al. SURMOUNT-1. NEJM 2022;387:205. (Tirzepatide 15 mg - 20.9% at 72 wk.)
• Aronne LJ et al. SURMOUNT-5. NEJM 2025 (May). (Tirzepatide -20.2% vs semaglutide -13.7% at 72 wk.)

Identifiers:

• AOD-9604 free base: CAS 386264-39-7; PubChem CID 71300630; UNII 7UP768IP4M.
• AOD-9604 acetate: PubChem CID 168310522.
• HGH Fragment 176-191 (for disambiguation only): CAS 66004-57-7; PubChem CID 172966176 (current).

Patents:

• WO2013082667 (Metabolic Pharmaceuticals) - Use of growth hormone fragments (intra-articular cartilage/muscle repair indication).
• US 10,758,593 / 10,111,933 (divisional continuations) - methods for muscle, ligament, or tendon mass/repair using peptide comprising hGH residues 182-189 / 177-191.

Community layer

Reddit / public-forum (May 2026 inventory; 1311 deduped records):

• r/Peptides 1phsd5j (2025-12-08, score 26, 14 comments): “Is AOD actually doing anything for you guys, or am I expecting too much?” - the freshest published-in-community confirmation of the dominant null signal.
• r/Peptides 1jpjj56 (2025-04-02, score 7, low engagement): “AOD9604 - Different formula and CAS number” - trace example of AOD-9604 / HGH Fragment 176-191 identity confusion at vendor level.
• r/Peptides 1moij72 (2025-08-12, score 16, 31 comments): “AOD-9604 keeps gelling after reconstitution - need advice” - pharmaceutical handling problem.
• r/Peptides 13qz0jc (2023-05-24, score 6, 37 comments): “AOD9604 (lipolytic GH fragment) requires a weak acid to dissolve properly” - community-discovered acetic-acid workaround.
• r/Peptides 1ljzhud (2025-06-25, score 26, 22 comments): “Lab tests are in!” - member shares actual bloodwork after 6 weeks on AOD + Tesa + Ipa + Tirz.
• r/Peptides 1lcj57t (2025-06-16, score 90, 25 comments): “My peptide progress!” - 230 → 175 → 183 lb over 13 months on a multi-peptide stack including AOD-9604.
• r/Peptides 1ldr0oz (2025-06-17, score 5, 10 comments): “Why AOD-9604 Might Not Work for You (And How to Check Your SNPs)” - community SNP/beta-3-AR theorising.
• r/Peptides 1hdck2n (2024-12-13, score 9, 12 comments): “AOD-9604 and Smart Scales” - body-composition anecdote on Tirz + AOD.
• r/Peptides 15g6t1z (2023-08-02, score 18, 34 comments): “Lowest dose of AOD9604 = most weight loss?” - mirrors the OBESE 1 mg-arm finding at community level.
• r/Peptides 1kb0j06 (2025-04-29, score 0, 11 comments): “AOD-9604 for double chin?!” - novel off-label cosmetic application.
• r/Peptides 13wdit6 (2023-05-31, score 0, 37 comments): “AOD9604 w/Semaglutide Results?” - canonical 2024-26 stack documentation.
• r/Peptides mgjzjt (2021-03-30, score 10, 24 comments): “Are Peptide Nasal Sprays legit like this AOD-9604 one?” - community legitimacy question.
• AnabolicMinds “Anyone Ever Heard Of AOD9604?” - multi-year thread; “Either bunk or doesn’t work. Save your money imo.”
• Eroids 2022 AOD-vs-HGH-Frag identity thread - AOD-9604 vs HGH Frag 176-191 identity question.
• EliteFitness “AOD 9604 Reconstitute” (2023-01-11/12) - 300 mcg/day SC protocol.
• BigFooty “Don’t be misled: AOD9604 is definitely a performance-enhancing drug” - Australian fan-culture dissent.

Biohacker / podcast:

• Jay Campbell, “AOD9604 and Semaglutide Stack” and “AOD 9604 vs Tirzepatide” (2021-2022, COI affiliate links).
• Ben Greenfield Podcast, “Best of Peptides,” guest Kyal Van Der Leest.

Clinic / vendor / press archive:

• Padgett Medical Ocala, Age Management of West Michigan, Beverly Hills Rejuvenation Center, Perfect B Doral, Gruene Road Pharmacy, American Medical Wellness, LIVV Natural, Colorado Medical Solutions, Tailor Made Compounding, Texas Best Compounding, Peptide Works (clinic / vendor, COI).
• Edge Peptides, Core Peptides, Limitless Life, Peptide Sciences, Biotech Peptides, Pure Health Peptides, Peptide Crafters (research-chem vendors, COI).
• Fairfax Media (Nick McKenzie), “Essendon coach ‘injected drugs’” (April 2013) - Stephen Dank’s direct admission re AOD-9604 on Essendon AFL players.
• Lexology, “AOD-9604: patents, peptides, performance and… cellulite?” (2013) - Gary Wittert IV-euphoria/antidepressant patent anecdote.
• Wikipedia, “Essendon Football Club supplements saga” - 12 January 2016 CAS guilty verdict on 34 players on Thymosin beta-4 basis.
• Reed Smith / Lexology (October 2024) - FDA’s 27 September 2024 procedural withdrawal of AOD-9604 from Category 2.
• Frier Levitt, “FDA Peptide Regulation” - enforcement summary.
• Mr Supplement Australia, “AOD9604 Peptide Facts” - community wiki / indirect source.

Retrieval limitations

Reddit / public-forum evidence was retrieved through Arctic Shift / PullPush with Arctic Shift parent-thread recovery attempted for top thread IDs. Capture is snapshot-based (May 2026), query-dependent, and skewed toward r/Peptides (1239 of 1311 deduped records). Top thread candidates were verified at permalink level. Comment-level records without recovered parent-thread metadata are used only as secondary signal. Cluster tags are heuristic. These records are community signal only, not efficacy or safety evidence. Compounding-pharmacy practitioner-login pricing for AOD-9604 troches/creams at Tailor Made, Empower, AnazaoHealth and BioPharma is gated; only product-existence is confirmed. No dedicated Huberman / Attia / Derek MPMD / Tony Huge / Layne Norton podcast episode on AOD-9604 was identified. Per-batch COA inspection at vendor pages was not performed in this pass; purity claims are taken from marketing copy.

The verbatim PCAC 2024-12-04 Topic 2 Committee Discussion transcript section was not fully extracted in Pass 1; specific voting rationales from temporary voters Drs Charles Billington and Susan Yanovski are not quoted verbatim. The FDA GRAS Notice 429 “no questions” response-letter date is not independently verified in this pass. No standalone full-length peer-reviewed publication of the OPTIONS Phase 2b primary outcome exists.

---

14. Audit / Refresh Trail

• Composed: 2026-05-20
• Pass 1 (Science) file: aod9604_sci_2026-05-20_D09.md; review date 2026-05-20.
• Pass 2A (Reddit / public-forum inventory) files: aod9604_reddit_inventory.csv, aod9604_reddit_inventory.json, aod9604_reddit_digest.md; snapshot date 2026-05-20. 1311 deduped records (594 submissions, 717 comments) via Arctic Shift / PullPush.
• Pass 2B (Community synthesis) file: aod9604_com_2026-05-20_B62.md; snapshot date 2026-05-20. The earlier “Reddit primary sources could not be retrieved at named-source resolution” limitation is now resolved by Pass 2A.
• Regulatory review date: 2026-05-20.
• Community review date: 2026-05-20.
• Next refresh triggers: (1) Lateral Pharma OA programme registration in any major trial registry; (2) FDA Warning Letter cadence specifically naming AOD-9604 in distinct enforcement actions; (3) WADA detection-assay harmonisation across labs; (4) any independent (non-Metabolic-network) human-trial publication; (5) any future PCAC re-nomination attempt; (6) emergence of a peer-reviewed full-length primary publication of the OPTIONS Phase 2b dataset.
• Two-molecule calibration status: active. Identity warning type = sequence/fragment confusion. AOD-9604 (Tyr-hGH 177-191, CAS 386264-39-7, MW ~1815.1 Da) vs HGH Fragment 176-191 (CAS 66004-57-7, MW ~1799 Da). Mirrored in identity_warnings.
• Calibration anchors used: TB-500 (two-molecule ambiguity / sequence-fragment confusion); BPC-157 (single-group dependency 🔴 - the Ng/Heffernan/Monash group methodologically parallel to the Sikiric group); distinctive AOD-9604 anchor (High community + Low science: tested negative or mixed - pivotal Phase 2b was run and failed, rare in this catalogue).
• Gap-matrix subclass assignment: primary = High community + Low science (tested negative or mixed); secondary = identity-conflation; tertiary = single-group dependency.
• Structured fields left needs_review: true: claim_profiles[visceral_fat_lipodystrophy].needs_review, claim_profiles[skin_aging_cosmetic].needs_review. Both are sub-patterns of the primary obesity claim that warrant separate review when independent data emerge.